A second trial is assessing the efficacy, safety, tolerability, and pharmacokinetics of ABBV-8E12 (AbbVie), a humanized anti-Tau antibody [34], in patients with progressive supranuclear palsy (PSP), an atypical parkinsonian syndrome (NCT02985879). Here, MAPT is linked to progressive supranuclear palsy.